Skip to main content
SP5007,691.76-0.69%DOW53,343.40-0.22%NASDAQ26,289.71-1.33%BTC$64,489.00+0.25%ETH$1,913.40+0.26%GOLD$4,397.30-0.53%OIL$84.77+0.84%
Smart Investors Daily
Sign InSign Up Free
XO

NYSE · XOMAO

XOMA Corporation

Healthcare · Biotechnology

$25.00

Up+$0.00 (+0.00%)

Updated Aug 19, 2026, 9:18 AM

SID Score

3.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
305.76M
P/E ratio
16.64
Dividend yield
8.37%
52-week range
$24.92 – $26.40
Volume
4.4K
Avg. volume
5.86K

Price performance

XOMAO price history

1M range · 0 trading sessions · Daily adjusted prices

XOMAO does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest XOMAO news

The latest Smart Investors Daily articles mentioning XOMAO.

Stock researchCompany · Overview

XOMAO research

Overview

Company profile and research snapshot.

Company profile

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
XOMAO recent ratings
DateFirmRatingTarget
Apr 30, 2026HC Wainwright & Co.Neutral—
Mar 20, 2026HC Wainwright & Co.Buy—
Feb 24, 2026Leerink PartnersOutperform—
Dec 11, 2025HC Wainwright & Co.Buy—
Dec 11, 2025Leerink PartnersOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jun 12, 2026

XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date

EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced that its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s (i) 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) (the “Series A Preferred Stock”) (984,000 shares outstanding, CUSIP No. 98419J305) and (ii) depositary shares representing its 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: X

SeekingAlpha · May 25, 2026

Saying Goodbye To The XOMA Royalty PFDs

Ligand Pharmaceuticals will acquire XOMA Royalty for $739M, boosting EPS and offering preferred yield upside. Read more on XOMAO stock here.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By